BR112014004716A2 - montagem remota de nanopartículas direcionadas usando reações de hidrofosfonilação -eno/-ino de h-fosfonato - Google Patents
montagem remota de nanopartículas direcionadas usando reações de hidrofosfonilação -eno/-ino de h-fosfonatoInfo
- Publication number
- BR112014004716A2 BR112014004716A2 BR112014004716A BR112014004716A BR112014004716A2 BR 112014004716 A2 BR112014004716 A2 BR 112014004716A2 BR 112014004716 A BR112014004716 A BR 112014004716A BR 112014004716 A BR112014004716 A BR 112014004716A BR 112014004716 A2 BR112014004716 A2 BR 112014004716A2
- Authority
- BR
- Brazil
- Prior art keywords
- phosphonate
- remote assembly
- targeted nanoparticles
- hydrophosphonylation
- reactions
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 238000005927 hydrophosphonylation reaction Methods 0.000 title abstract 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161529665P | 2011-08-31 | 2011-08-31 | |
| PCT/US2012/053211 WO2013033450A2 (en) | 2011-08-31 | 2012-08-30 | Remote assembly of targeted nanoparticles using h-phosphonate-ene/-yne hydrophosphonylation reactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014004716A2 true BR112014004716A2 (pt) | 2017-03-28 |
Family
ID=46832627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014004716A BR112014004716A2 (pt) | 2011-08-31 | 2012-08-30 | montagem remota de nanopartículas direcionadas usando reações de hidrofosfonilação -eno/-ino de h-fosfonato |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9216225B2 (enExample) |
| EP (1) | EP2750711A2 (enExample) |
| JP (1) | JP2014525459A (enExample) |
| KR (1) | KR20140064917A (enExample) |
| CN (1) | CN103945869A (enExample) |
| BR (1) | BR112014004716A2 (enExample) |
| CA (1) | CA2845851A1 (enExample) |
| IL (1) | IL231216A0 (enExample) |
| WO (1) | WO2013033450A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9918190B2 (en) * | 2015-02-18 | 2018-03-13 | Cisco Technology, Inc. | Augmenting network device management |
| FR3046728B1 (fr) * | 2016-01-19 | 2020-04-03 | Centre National De La Recherche Scientifique | Nouvelles nanoparticules d'organosilice mesoporeuses, leur methode de preparation et leurs utilisations. |
| JPWO2019009434A1 (ja) * | 2017-07-06 | 2020-07-02 | 学校法人京都薬科大学 | 薬物送達用高分子ミセル |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940961A (en) * | 1957-08-09 | 1960-06-14 | Eastman Kodak Co | Alkyl 1-acetoxyalkenylphosphonates and polymers thereof |
| US3006945A (en) * | 1960-09-01 | 1961-10-31 | Ethyl Corp | Preparation of organic compounds |
| US3224973A (en) * | 1960-09-01 | 1965-12-21 | Ethyl Corp | Dialkyl hydroxybenzyl phosphonates as antioxidants |
| US3367870A (en) * | 1963-09-12 | 1968-02-06 | Geigy Chem Corp | Method of stabilization with carbonbonded phosphorus derivatives and compositions stabilized thereby |
| US3681481A (en) | 1969-11-12 | 1972-08-01 | Hooker Chemical Corp | Catalytic addition of compounds having a p-h bond to acetylene |
| FR2460958A1 (fr) * | 1979-07-09 | 1981-01-30 | Elf Aquitaine | Nouveaux composes diphosphoniques, utiles a l'extraction des metaux lourds |
| EP0023173B1 (fr) * | 1979-07-09 | 1983-12-14 | Societe Nationale Elf Aquitaine (Production) | Nouveaux esters diphosphoniques et triphosphoniques, leurs préparation et applications |
| US4820698A (en) * | 1985-11-04 | 1989-04-11 | The Procter & Gamble Company | Antimicrobial agents and process for their manufacture |
| US4798872A (en) * | 1986-04-28 | 1989-01-17 | Ashland Oil, Inc. | Alkylene phosphonate acid ester polyols |
| DE3643684A1 (de) * | 1986-12-20 | 1988-06-30 | Hoechst Ag | Verfahren zur herstellung von halogenierten phosphono-phosphorsaeureestern und ihre verwendung |
| DK637888A (da) * | 1987-11-24 | 1989-05-25 | Hoffmann La Roche | Carboxylsyreestere |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5321153A (en) * | 1992-06-15 | 1994-06-14 | Monsanto Company | Process for making chiral alpha-amino phosphonates selected novel chiral alpha-amino phosphonates |
| JPH07140615A (ja) * | 1993-11-12 | 1995-06-02 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー感光材料 |
| JPH07140606A (ja) * | 1993-11-19 | 1995-06-02 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| DE4410601A1 (de) * | 1994-03-26 | 1995-09-28 | Boehringer Mannheim Gmbh | Neue 2.4-Diphosphonoglutarsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| WO1996024599A1 (en) * | 1995-02-10 | 1996-08-15 | Akzo Nobel N.V. | Synthesis of a hydrocarbylvinyl phosphonic acid hydrocarbyl ester |
| JP2775426B2 (ja) * | 1995-09-14 | 1998-07-16 | 工業技術院長 | 不飽和ホスホン酸エステルの製造方法 |
| GB9613722D0 (en) * | 1996-06-28 | 1996-08-28 | Univ Liverpool | Chemical compounds |
| JP3007984B1 (ja) * | 1999-03-08 | 2000-02-14 | 工業技術院長 | 不飽和ホスホン酸エステルの製造方法 |
| DE60038038T2 (de) * | 1999-12-03 | 2009-02-12 | The Regents of The University of California at San Diego, La Jolla | Phosphonatverbindungen |
| JP3610371B2 (ja) * | 2000-03-13 | 2005-01-12 | 独立行政法人産業技術総合研究所 | （α−及び／又はβ−ホルミルエチル）ホスフィンオキシド化合物、（α−及び／又はβ−ホルミルエチル）ホスホン酸エステル化合物とその製造方法 |
| DE10049074A1 (de) | 2000-10-02 | 2002-04-18 | Andreas Kage | Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren |
| GB0025849D0 (en) * | 2000-10-23 | 2000-12-06 | Smithkline Beecham Plc | Novel compounds |
| DE10054218A1 (de) | 2000-11-02 | 2002-05-08 | Basf Ag | Verfahren zur Herstellung von Alkenylphosphonsäure-Derivaten |
| EP1506208A4 (en) * | 2002-05-11 | 2006-05-24 | Ilex Products Inc | USE OF 1,1 AND 1,2-DIPHOSPHONATES AS MODULATORS OF APOLIPOPROTEIN E |
| JP3836395B2 (ja) * | 2002-05-17 | 2006-10-25 | 独立行政法人科学技術振興機構 | アルケニルリン化合物の製造方法 |
| DE102004032781A1 (de) * | 2004-01-23 | 2005-08-11 | Mcs Micro Carrier Systems Gmbh | Bisphosphonsäurederivate |
| JP4314366B2 (ja) * | 2004-02-18 | 2009-08-12 | 独立行政法人産業技術総合研究所 | 含リンブタジエン化合物の製造方法 |
| WO2006078646A2 (en) | 2005-01-18 | 2006-07-27 | Caltagirone Gaetano T | A class of supramolecular drug molecules and methods of identification and use thereof |
| EP2019649A4 (en) * | 2006-04-27 | 2012-09-19 | Narmada R Shenoy | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING BODILUM DISORDER DISORDERS |
| CN1887890A (zh) * | 2006-07-17 | 2007-01-03 | 华中师范大学 | 具有除草活性的α－酰氧基烯基膦酸酯及制备 |
| CN1903862B (zh) * | 2006-07-20 | 2012-10-10 | 华中师范大学 | 具有除草活性的取代甲酰氧基烃基膦酸酯类光学活性异构体及制备 |
| FR2921838A1 (fr) * | 2007-10-05 | 2009-04-10 | Guerbet Sa | Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile |
| US8501980B2 (en) * | 2008-05-30 | 2013-08-06 | Sumitomo Chemical Company, Ltd. | Process for producing oseltamivir phosphate and intermediate compound |
| US9545452B2 (en) * | 2010-02-08 | 2017-01-17 | Board Of Regents Of The University Of Nebraska | Biomineral and metal binding liposomes, their synthesis, and methods of use thereof |
-
2012
- 2012-08-30 KR KR1020147007933A patent/KR20140064917A/ko not_active Withdrawn
- 2012-08-30 EP EP12758720.2A patent/EP2750711A2/en not_active Withdrawn
- 2012-08-30 US US13/599,777 patent/US9216225B2/en not_active Expired - Fee Related
- 2012-08-30 JP JP2014528613A patent/JP2014525459A/ja active Pending
- 2012-08-30 WO PCT/US2012/053211 patent/WO2013033450A2/en not_active Ceased
- 2012-08-30 CA CA2845851A patent/CA2845851A1/en not_active Abandoned
- 2012-08-30 CN CN201280053586.7A patent/CN103945869A/zh active Pending
- 2012-08-30 BR BR112014004716A patent/BR112014004716A2/pt not_active IP Right Cessation
-
2014
- 2014-02-27 IL IL231216A patent/IL231216A0/en unknown
-
2015
- 2015-11-12 US US14/939,064 patent/US20160060280A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014525459A (ja) | 2014-09-29 |
| KR20140064917A (ko) | 2014-05-28 |
| US20160060280A1 (en) | 2016-03-03 |
| WO2013033450A3 (en) | 2013-09-06 |
| CN103945869A (zh) | 2014-07-23 |
| US20130066098A1 (en) | 2013-03-14 |
| CA2845851A1 (en) | 2013-03-07 |
| US9216225B2 (en) | 2015-12-22 |
| EP2750711A2 (en) | 2014-07-09 |
| WO2013033450A2 (en) | 2013-03-07 |
| IL231216A0 (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14013329A (es) | Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas | |
| BR112015007365A2 (pt) | Processo para a preparação de um hidrogel, pró-droga ligada a um suporte e composição farmacêutica | |
| CO7200281A2 (es) | Composicion para control de enfermedades de plantas y aplicacion para la misma | |
| AR087451A1 (es) | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes | |
| BR112015014555A2 (pt) | composições pesticidas e processos relacionados a isso | |
| BR112015029090A2 (pt) | compostos de 3,4-di-hidroisoquinolin-2(1h)-ila | |
| BR112014027359A2 (pt) | moduladores da série de reação complementar e usos dos mesmos | |
| CO6571889A2 (es) | Antidotos anticoagulantes | |
| BR112013028449A2 (pt) | composições compreendendo partículas de hidrogel | |
| BR112013023536A2 (pt) | agentes antimicrobianos | |
| BR112014027303A2 (pt) | identificação de variantes de isopreno sintase com propriedades optimizadas para a produção de isopreno | |
| BR112014003806A2 (pt) | polímeros de adsorção de sujeira | |
| HK1221418A1 (zh) | 释放修饰药物的水凝胶-连接的前药 | |
| BR112012018775A8 (pt) | microprocessamento para a preparação de um policondensado | |
| BR112015000329A2 (pt) | formulações de diclofenac | |
| BR112015021388A2 (pt) | conjugados esteroides de ciclosporina a | |
| BR112014005935A2 (pt) | derivados de anilina, sua preparação e sua aplicação terapêutica | |
| BR112013001111A2 (pt) | processo para a produção do composto da fórmula 1, processo para a produção de um composto da fórmula a, processo para a produção dos compostos da fórmula d, composto da fórmula e, composto da fórmula f e novos compostos | |
| BR112015013615A2 (pt) | plantas de melão com resistência ao vírus associado ao amarelecimento do melão (myav) | |
| BR112013002591A2 (pt) | polialfaolefinas de elevada viscosidade estáveis em cisalhamento | |
| BR122018074319B8 (pt) | Método para preparar um composto de fórmula 14 | |
| BR112015002275A2 (pt) | processos e intermediários para a preparação de inibidores da integrase | |
| BR112015011798A2 (pt) | métodos e composições para tratar doenças neurodegenerativas | |
| BR112013029149A2 (pt) | processo de produção de material inorgânico em partículas | |
| GT201400242A (es) | "nuevos compuestos de pirazol" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07F 9/40 (2006.01), A61K 47/54 (2017.01), A61K 47 |